VectorBuilder's partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy ...

Just a few months after Vir Biotechnology lost an emergency authorization for its COVID-19 antibody, Marianne de Backer ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

In addition to its extensive FDA IND experience with transfection-based lentiviral vector processes, VectorBuilder has established a robust system to adopt advanced technologies, enabling the ...

The FDA argued the law gave it the authority to ... Imperial Brands' (IMB.L), opens new tab subsidiary ITG Brands and Vector Group's Liggett Group unit. R.J. Reynolds and the FDA declined to ...

In summary, enalapril significantly mitigated multiple pathological markers associated with aging, including lipid droplets, amyloid, glycogen deposition, and fibrosis, in the brain, kidneys, liver, ...

which is part of British American Tobacco and had sued in 2020 alongside Imperial Brands' subsidiary ITG Brands and Vector Group's Liggett Group unit. R.J. Reynolds and the FDA declined to comment.

Pluristyx, a leading provider of innovative, unmodified, and gene-edited induced pluripotent stem cell (iPSC) lines, submitted a Type II Drug Master File (DMF) to the U.S. Food and Drug Administration ...

approval from the U.S. Food and Drug Administration (FDA) on January 11, 2025. VectorBuilder has provided highly customized end-to-end CDMO solutions to support this clinical pipeline.

The Biden White House is expected to formally propose a plan ordering cigarette nicotine levels to be reduced dramatically.